Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 247COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchInflammation biomarkers and pathways

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity

Open access

Abstract

Epidemiological and clinical reports indicate that SARS-CoV-2 virulence hinges upon the triggering of an aberrant host immune response, more so than on direct virus-induced cellular damage. To elucidate the immunopathology underlying COVID-19 severity, we perform cytokine and multiplex immune profiling in COVID-19 patients. We show that hypercytokinemia in COVID-19 differs from the interferon-gamma-driven cytokine storm in macrophage activation syndrome, and is more pronounced in critical versus mild-moderate COVID-19. Systems modelling of cytokine levels paired with deep-immune profiling shows that classical monocytes drive this hyper-inflammatory phenotype and that a reduction in T-lymphocytes correlates with disease severity, with CD8+ cells being disproportionately affected. Antigen presenting machinery expression is also reduced in critical disease. Furthermore, we report that neutrophils contribute to disease severity and local tissue damage by amplification of hypercytokinemia and the formation of neutrophil extracellular traps. Together our findings suggest a myeloid-driven immunopathology, in which hyperactivated neutrophils and an ineffective adaptive immune system act as mediators of COVID-19 disease severity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-24360-w

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Hypercytokinemia in COVID-19 as a distinct cytokine release syndrome. Comparison of plasma levels of selected cytokines and chemokines from healthy controls (HC, n = 10), COVID-19 critical condition (CCC, n = 22) and MAS patients (n = 10) (a) and COVID-19 subgroups (for mild-moderate (CMM), n = 39; for critical (CCC), n = 22) versus healthy controls (n = 10) (b). Plasma concentrations were measured by MSD (Meso Scale Discovery). Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Kruskal–Wallis test with Dunn’s correction for multiple comparisons was used; IL-6: p < 0.0001 HC vs CCC, p = 0.003 HC vs MAS; IL-18: p < 0.0001 HC vs MAS, p = 0.005 CCC vs MAS; IFNg: p = 0.014 HC vs CCC, p < 0.0001 HC vs MAS, p = 0.008 CCC vs MAS; TNF-a: p = 0.004 HC vs CCC, p < 0.0001 HC vs MAS, p = 0.015 CCC vs MAS; CXCL8: p = 0.008 HC vs CCC, p = 0.002 CCC vs MAS; CXCL9: p = 0.007 HC vs CCC, p < 0.0001 HC vs MAS, p = 0.014 CCC vs MAS; VEGF: p = 0.049 HC vs CCC, p = 0.0004 CCC vs MAS (a) and IL-6: p = 0.0009 HC vs CMM, p < 0.0001 HC vs CCC, p = 0.014 CMM vs CCC; IL-18: p = 0.019 HC vs CCC, p = 0.024 CMM vs CCC; IFNg: p = 0.004 HC vs CMM, p = 0.003 HC vs CCC; TNF-a: p = 0.009 HC vs CMM, p < 0.0001 HC vs CCC, p = 0.038 CMM vs CCC; CCL2: p = 0.003 HC vs CMM, p < 0.0001 HC vs CCC, p = 0.026 CMM vs CCC; CCL3: p = 0.006 HC vs CMM, p < 0.0001 HC vs CCC, p = 0.016 CMM vs CCC; CXCL8: p = 0.007 HC vs CMM, p = 0.0005 HC vs CCC (b). Significance is shown as *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001. MAS = macrophage activation syndrome. See Figs. S1 and S2 for additional cytokine results. Source data are provided as a Source data file.
Fig. 1 Hypercytokinemia in COVID-19 as a distinct cytokine release syndrome. Comparison of plasma levels of selected cytokines and chemokines from healthy controls (HC, n = 10), COVID-19 critical condition (CCC, n = 22) and MAS patients (n = 10) (a) and COVID-19 subgroups (for mild-moderate (CMM), n = 39; for critical (CCC), n = 22) versus healthy controls (n = 10) (b). Plasma concentrations were measured by MSD (Meso Scale Discovery). Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Kruskal–Wallis test with Dunn’s correction for multiple comparisons was used; IL-6: p < 0.0001 HC vs CCC, p = 0.003 HC vs MAS; IL-18: p < 0.0001 HC vs MAS, p = 0.005 CCC vs MAS; IFNg: p = 0.014 HC vs CCC, p < 0.0001 HC vs MAS, p = 0.008 CCC vs MAS; TNF-a: p = 0.004 HC vs CCC, p < 0.0001 HC vs MAS, p = 0.015 CCC vs MAS; CXCL8: p = 0.008 HC vs CCC, p = 0.002 CCC vs MAS; CXCL9: p = 0.007 HC vs CCC, p < 0.0001 HC vs MAS, p = 0.014 CCC vs MAS; VEGF: p = 0.049 HC vs CCC, p = 0.0004 CCC vs MAS (a) and IL-6: p = 0.0009 HC vs CMM, p < 0.0001 HC vs CCC, p = 0.014 CMM vs CCC; IL-18: p = 0.019 HC vs CCC, p = 0.024 CMM vs CCC; IFNg: p = 0.004 HC vs CMM, p = 0.003 HC vs CCC; TNF-a: p = 0.009 HC vs CMM, p < 0.0001 HC vs CCC, p = 0.038 CMM vs CCC; CCL2: p = 0.003 HC vs CMM, p < 0.0001 HC vs CCC, p = 0.026 CMM vs CCC; CCL3: p = 0.006 HC vs CMM, p < 0.0001 HC vs CCC, p = 0.016 CMM vs CCC; CXCL8: p = 0.007 HC vs CMM, p = 0.0005 HC vs CCC (b). Significance is shown as *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001. MAS = macrophage activation syndrome. See Figs. S1 and S2 for additional cytokine results. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 2 Peripheral blood immunophenotyping. a Heatmap representation of immune cell subset changes between healthy controls (n = 8), COVID-19 mild-moderate (n = 32) and critical (n = 14) condition based on mass cytometry measurements on whole blood; representation shows relative fold change compared to healthy per cell subset. A two-sided Wilcoxon rank-sum test with Benjamini–Hochberg correction for multiple group comparisons was used. b scRNA-seq data of COVID-19 PBMCs: UMAP plot of 83,524 single cells, colour-coded per cell type. c Violin plots of expression level of key cytokine/chemokine/chemokine receptor coding genes in the cell types identified in PBMCs from COVID-19 patients, as shown in (b). d CD4+/CD8+ ratios in healthy controls (HC, n = 6), mild-moderate (CMM, n = 13) and critical (CCC, n = 10) COVID-19 cases, based on scRNA-seq. Healthy control data were derived from a publicly available dataset (GSE150728). Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test with Benjamini–Hochberg correction for multiple group comparisons was used. p = 0.002 HC vs CMM, p = 0.011 HC vs CCC. Significance is shown as *p < 0.05; **p < 0.01. See Figs. S4 and S5 for further supporting data. Source data are provided as a Source data file.
Fig. 2 Peripheral blood immunophenotyping. a Heatmap representation of immune cell subset changes between healthy controls (n = 8), COVID-19 mild-moderate (n = 32) and critical (n = 14) condition based on mass cytometry measurements on whole blood; representation shows relative fold change compared to healthy per cell subset. A two-sided Wilcoxon rank-sum test with Benjamini–Hochberg correction for multiple group comparisons was used. b scRNA-seq data of COVID-19 PBMCs: UMAP plot of 83,524 single cells, colour-coded per cell type. c Violin plots of expression level of key cytokine/chemokine/chemokine receptor coding genes in the cell types identified in PBMCs from COVID-19 patients, as shown in (b). d CD4+/CD8+ ratios in healthy controls (HC, n = 6), mild-moderate (CMM, n = 13) and critical (CCC, n = 10) COVID-19 cases, based on scRNA-seq. Healthy control data were derived from a publicly available dataset (GSE150728). Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test with Benjamini–Hochberg correction for multiple group comparisons was used. p = 0.002 HC vs CMM, p = 0.011 HC vs CCC. Significance is shown as *p < 0.05; **p < 0.01. See Figs. S4 and S5 for further supporting data. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 3 Reduced MHC class II on antigen-presenting cells marks critical COVID-19. a Heatmap of differential monocyte clusters between healthy (n = 8), mild-moderate (n = 32) and critical (n = 14) COVID-19 groups based on mass cytometry measurements on whole blood. Rows indicate monocyte subclusters. Columns indicate patient groups (left) and cell surface markers (right). A two-sided Wilcoxon rank-sum test with Benjamini–Hochberg correction for multiple group comparisons was used. b HLA-DR expression on CD14hi monocytes in healthy (HC, n = 6; mean 95,72%), mild-moderate (CMM, n = 21; mean 84,14%) and critical (CCC, n = 20; mean 70,97%) groups based on flow cytometric analyses of PBMCs. Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test with Benjamini–Hochberg correction for multiple group comparisons was used; p = 0.0014 HC vs CCC, p = 0.046 CMM vs CCC. c Gene set enrichment analysis of HLA-DR complex coding genes in professional antigen-presenting cells, comparing scRNA-seq data from mild-moderate (n = 13) and critical (n = 10) COVID-19 cases. Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test was used, p = 0.0303 for dendritic cells (DC). d Expression of HLA-DR on myeloid DC based on mass cytometry measurements (mild-moderate n = 32, critical n = 14). Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test was used, p = 0.0098. e Heatmap of genes coding for co-stimulatory molecules involved in MHC class II-restricted antigen presentation by dendritic cells, comparing mild-moderate versus critical COVID-19. Individual dots in boxplots represent data points per patient. Source data are provided as a Source data file. Statistical significance is shown as *p < 0.05; **p < 0.01.
Fig. 3 Reduced MHC class II on antigen-presenting cells marks critical COVID-19. a Heatmap of differential monocyte clusters between healthy (n = 8), mild-moderate (n = 32) and critical (n = 14) COVID-19 groups based on mass cytometry measurements on whole blood. Rows indicate monocyte subclusters. Columns indicate patient groups (left) and cell surface markers (right). A two-sided Wilcoxon rank-sum test with Benjamini–Hochberg correction for multiple group comparisons was used. b HLA-DR expression on CD14hi monocytes in healthy (HC, n = 6; mean 95,72%), mild-moderate (CMM, n = 21; mean 84,14%) and critical (CCC, n = 20; mean 70,97%) groups based on flow cytometric analyses of PBMCs. Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test with Benjamini–Hochberg correction for multiple group comparisons was used; p = 0.0014 HC vs CCC, p = 0.046 CMM vs CCC. c Gene set enrichment analysis of HLA-DR complex coding genes in professional antigen-presenting cells, comparing scRNA-seq data from mild-moderate (n = 13) and critical (n = 10) COVID-19 cases. Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test was used, p = 0.0303 for dendritic cells (DC). d Expression of HLA-DR on myeloid DC based on mass cytometry measurements (mild-moderate n = 32, critical n = 14). Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test was used, p = 0.0098. e Heatmap of genes coding for co-stimulatory molecules involved in MHC class II-restricted antigen presentation by dendritic cells, comparing mild-moderate versus critical COVID-19. Individual dots in boxplots represent data points per patient. Source data are provided as a Source data file. Statistical significance is shown as *p < 0.05; **p < 0.01.CC BY · PubMed Central
Fig. 4 Disturbed immune regulation in severe COVID-19. Pearson correlation-driven similarity/correlation matrix analysis of cytokines/chemokines and mass cytometry data in critical (n = 14) (a) and mild-moderate (n = 31) (b) COVID-19 patient subgroups. This correlation matrix analysis is a form of statistical modelling by which statistically stable relationships between the different variables (i.e. cytokines/chemokines and immune cell subpopulations) allows their categorization into different clusters indicating high levels of correlation (indicated by the clustering dendrograms). Of note, the diagonal correlation value is 1, which denotes the highest possible statistically significant correlation value between the given variables and represents the highest comparative threshold that “centers” the correlation network. See also Fig. S3. Source data are provided as a Source data file.
Fig. 4 Disturbed immune regulation in severe COVID-19. Pearson correlation-driven similarity/correlation matrix analysis of cytokines/chemokines and mass cytometry data in critical (n = 14) (a) and mild-moderate (n = 31) (b) COVID-19 patient subgroups. This correlation matrix analysis is a form of statistical modelling by which statistically stable relationships between the different variables (i.e. cytokines/chemokines and immune cell subpopulations) allows their categorization into different clusters indicating high levels of correlation (indicated by the clustering dendrograms). Of note, the diagonal correlation value is 1, which denotes the highest possible statistically significant correlation value between the given variables and represents the highest comparative threshold that “centers” the correlation network. See also Fig. S3. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 5 Contribution of neutrophils to COVID-19 immunopathology at a local level: scRNA-seq data of COVID-19 BAL fluid. UMAP plot of 26,605 single cells (from 11 patients, n = 6 for COVID-19, n = 5 for non-COVID pneumonia), colour-coded per cell type (a) and UMAP showing active and resting neutrophil subclusters (b) present in the bronchoalveolar lavage fluid of COVID-19 and non-COVID pneumonia patients. c Feature plots of key differentially expressed genes, with IL1B, CXCL8 and S100A12 being upregulated in the active neutrophil population. d Boxplots showing a significant abundance of active neutrophils in COVID-19 pneumonitis, as compared to non-COVID pneumonia. Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test was used, p = 0.009 active neutrophils COVID vs Non-COVID pneumonia. e Relative immune cell type abundance in bronchoalveolar lavage fluid of COVID-19, compared to non-COVID pneumonia. Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test was used, p = 0.017 neutrophils COVID vs non-Covid pneumonia. Source data are provided as a Source data file. Significance is shown as *p < 0.05; **p < 0.01. See also Fig. S8.
Fig. 5 Contribution of neutrophils to COVID-19 immunopathology at a local level: scRNA-seq data of COVID-19 BAL fluid. UMAP plot of 26,605 single cells (from 11 patients, n = 6 for COVID-19, n = 5 for non-COVID pneumonia), colour-coded per cell type (a) and UMAP showing active and resting neutrophil subclusters (b) present in the bronchoalveolar lavage fluid of COVID-19 and non-COVID pneumonia patients. c Feature plots of key differentially expressed genes, with IL1B, CXCL8 and S100A12 being upregulated in the active neutrophil population. d Boxplots showing a significant abundance of active neutrophils in COVID-19 pneumonitis, as compared to non-COVID pneumonia. Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test was used, p = 0.009 active neutrophils COVID vs Non-COVID pneumonia. e Relative immune cell type abundance in bronchoalveolar lavage fluid of COVID-19, compared to non-COVID pneumonia. Boxplot representation (centre line, mean; box limits, upper and lower quartiles; whiskers, range; points, data points per patient). A two-sided Wilcoxon rank-sum test was used, p = 0.017 neutrophils COVID vs non-Covid pneumonia. Source data are provided as a Source data file. Significance is shown as *p < 0.05; **p < 0.01. See also Fig. S8.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 91 references

Cited by

See all 247

Metadata

Authors
Vanderbeke, L., Van Mol, P., Van Herck, Y., De Smet, F., Humblet-Baron, S., Martinod, K., Antoranz, A., Arijs, I., Boeckx, B., Bosisio, F. M., Casaer, M., Dauwe, D., De Wever, W., Dooms, C., Dreesen, E., Emmaneel, A., Filtjens, J., Gouwy, M., Gunst, J., Hermans, G., Jansen, S., Lagrou, K., Liston, A., Lorent, N., Meersseman, P., Mercier, T., Neyts, J., Odent, J., Panovska, D., Penttila, P. A., Pollet, E., Proost, P., Qian, J., Quintelier, K., Raes, J., Rex, S., Saeys, Y., Sprooten, J., Tejpar, S., Testelmans, D., Thevissen, K., Van Buyten, T., Vandenhaute, J., Van Gassen, S., Velásquez Pereira, L. C., Vos, R., Weynand, B., Wilmer, A., Yserbyt, J., Garg, A. D., Matthys, P., Wouters, C., Lambrechts, D., Wauters, E., & Wauters, J.
Affiliations
  • KU Leuven (BE)
  • VIB-UGent Center for Inflammation Research (BE)
  • Rega Institute for Medical Research (BE)
  • Babraham Institute (GB)
  • Universitair Ziekenhuis Leuven (BE)
  • VIB-KU Leuven Center for Microbiology (BE)
Corresponding author
Wauters, E.
Venue
Nature Communications
Published
2021-07-05
Volume
12
Issue
1
Pages
4117-4117
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3091384134
Cited by
247
References
91
Citations by year
2026: 12 · 2025: 25 · 2024: 50 · 2023: 48 · 2022: 86 · 2021: 24
FWCI
17.02
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • Vlaams Supercomputer Centrum
  • Fonds Wetenschappelijk Onderzoek (C14/17/084, 1S66020N, I007418N, 12X9420N, 11E9819N, C16/17/010)
  • KU Leuven (11E9819N, C16/17/010, C14/17/084)
  • Vlaamse regering (C16/17/010)
  • Rega Foundation
  • Universitaire Ziekenhuizen Leuven, KU Leuven (C16/17/010)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords
COVID-19 pandemic, SARS-CoV-2, cytokine storm, classical monocytes, neutrophil activation, neutrophil extracellular traps, disease severity, CD8+ T cells, T cell depletion, antigen presentation, hyperinflammation, macrophage activation syndrome, interferon-gamma
MeSH terms
Cytokine Release Syndrome, COVID-19, SARS-CoV-2, Aged, Antigen-Presenting Cells, Histocompatibility Antigens Class II, Female, Humans, Male, Middle Aged, Monocytes, Severity of Illness Index, Case-Control Studies, Immunophenotyping, Cytokines, Neutrophil Activation, Extracellular Traps

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. https://app.cochat.ai/papers/10.1038/s41467-021-24360-w
The paper
Vanderbeke, L., Van Mol, P., Van Herck, Y., De Smet, F., Humblet-Baron, S., Martinod, K., Antoranz, A., Arijs, I., Boeckx, B., Bosisio, F. M., Casaer, M., Dauwe, D., De Wever, W., Dooms, C., Dreesen, E., Emmaneel, A., Filtjens, J., Gouwy, M., Gunst, J., . . . Wauters, J. (2021). Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nature Communications. https://doi.org/10.1038/s41467-021-24360-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.